Bayer teams up with biotech firm Arvinas in deal worth up to $750 million
Arvinas is working on so-called proteolysis targeting chimeras that harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
More from Missouri Business
The Missourian | Business
MU Health Care officials say cuts will help support long term financial stability
Missouri Business
•
Jun 19, 2026
The Missourian | Business
March basketball brings betting bounce as Missouri wagers, tax revenue jump
Missouri Business
•
May 5, 2026
The Missourian | Business
State funding uncertainty forces child care centers to weigh their options
Missouri Business
•
Apr 25, 2026
The Missourian | Business
InvestMidwest works to boost region's startups with 'eyeball-to-eyeball' interaction
Missouri Business
•
Apr 21, 2026
The Missourian | Business
March inflation surges as gasoline costs soar amid Iran war
Missouri Business
•
Apr 13, 2026
The Missourian | Business
Company behind gas station slot machines suspending operations amid criminal probe
Missouri Business
•
Apr 10, 2026
The Missourian | Business
Missouri records strongest February cannabis sales since legalization
Missouri Business
•
Apr 7, 2026
The Missourian | Business
Missouri Women's Business Center celebrates first decade
Missouri Business
•
Feb 28, 2026